Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389857 · ClinicalTrials.gov registry record · Phase 4
Trial to Collect Safety Data and Sera for Immunogenicity Testing
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00389857 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 31 participants.
The verdict
NCT00389857, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
To provide Centers for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by the Food and Drug Administration (FDA), Center for Disease Control and Prevention (CDC) and World Health Organization (WHO).
Interventions
- BIOLOGICAL Influenza Virus Vaccine (Fluzone®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389857
The ClinicalTrials.gov registry entry for NCT00389857 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine (Fluzone®) is the first listed.
NCT00389857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389857 about?
NCT00389857 is a clinical study titled "Trial to Collect Safety Data and Sera for Immunogenicity Testing". To provide Centers for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by the Food and Drug Administration (FDA), Center for Disease Control and Preven...
What is the current status of trial NCT00389857?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00389857?
The interventions under investigation include: Influenza Virus Vaccine (Fluzone®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00389857?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.